CSIMarket
 


Theriva Biologics inc   (TOVX)
Other Ticker:  
 

Theriva Biologics Inc 's Working Capital Ratio

TOVX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Current Liabilities decreased faster than Theriva Biologics Inc 's Current Assets, this led to improvement in Theriva Biologics Inc 's Working Capital Ratio to 4.07, Working Capital Ratio remained below Theriva Biologics inc average.

Within Major Pharmaceutical Preparations industry 307 other companies have achieved higher Working Capital Ratio than Theriva Biologics Inc in forth quarter 2023. While Working Capital Ratio total ranking in the forth quarter 2023 has deteriorated compared to the prior quarter from 1202 to 1247.

Explain Working Capital Ratio
How much in Current Assets TOVX´s has?
What is the value of TOVX´s Current Liabilities?


TOVX Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -48.92 % -34.08 % -16.78 % 142.52 % 317.47 %
Y / Y Current Assets Change -48.03 % -36.66 % -36.25 % -41.48 % -28.31 %
Working Capital Ratio MRQ 4.07 3.98 4.16 4.68 4
TOVX's Total Ranking # 1247 # 1202 # # 1657 # 1735
Seq. Current Liabilities Change -22.93 % -4.28 % 5.98 % -34.66 % -0.54 %
Seq. Current Assets Change -21.18 % -8.42 % -5.79 % -23.58 % -3.93 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 308
Healthcare Sector # 552
Overall Market # 1271


Working Capital Ratio Statistics
High Average Low
58.44 9.57 0.46
(Mar 31 2013)   (Jun 30 2015)




Financial Statements
Theriva Biologics Inc 's Current Liabilities $ 7 Millions Visit TOVX's Balance sheet
Theriva Biologics Inc 's Current Assets $ 27 Millions Visit TOVX's Balance sheet
Source of TOVX's Sales Visit TOVX's Sales by Geography


Cumulative Theriva Biologics Inc 's Working Capital Ratio

TOVX's Working Capital Ratio for the trailling 12 Months

TOVX Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -48.92 % -34.08 % -16.78 % 142.52 % 317.47 %
Y / Y Current Assets TTM Growth -48.03 % -36.66 % -36.25 % -41.48 % -28.31 %
Working Capital Ratio TTM 4.23 4.18 4.2 4.51 5.76
Total Ranking TTM # 900 # 916 # # 849 # 706
Seq. Current Liabilities TTM Growth -22.93 % -4.28 % 5.98 % -34.66 % -0.54 %
Seq. Current Assets TTM Growth -21.18 % -8.42 % -5.79 % -23.58 % -3.93 %


On the trailing twelve months basis Current Liabilities decreased faster than Theriva Biologics Inc 's average Current Assets, this led to increase in in Theriva Biologics Inc 's Working Capital Ratio to 4.23, Working Capital Ratio remained below TOVX average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 516 other companies have achieved higher Working Capital Ratio than Theriva Biologics Inc . While Working Capital Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending third quarter 2023 at 859.

Explain Working Capital Ratio
How much in Current Assets TOVX´s has?
What is the value of TOVX´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 517
Healthcare Sector # 1073
Within the Market # 1247


trailing twelve months Working Capital Ratio Statistics
High Average Low
27.13 6.68 1.14
(Dec 31 2021)   (Sep 30 2017)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Cymabay Therapeutics Inc   10.96 $ 403.802  Millions$ 36.843  Millions
Ovid Therapeutics Inc   10.72 $ 109.598  Millions$ 10.228  Millions
Spyre Therapeutics Inc   10.68 $ 341.528  Millions$ 31.978  Millions
Chimerix Inc   10.25 $ 189.110  Millions$ 18.443  Millions
Aprea Therapeutics Inc   10.24 $ 22.521  Millions$ 2.199  Millions
Milestone Pharmaceuticals inc   10.11 $ 73.032  Millions$ 7.226  Millions
Summit Therapeutics Inc   9.30 $ 189.712  Millions$ 20.405  Millions
Ac Immune Sa  9.22 $ 125.153  Millions$ 13.576  Millions
Sol gel Technologies Ltd   9.10 $ 41.167  Millions$ 4.522  Millions
Oncolytics Biotech Inc   9.01 $ 29.241  Millions$ 3.246  Millions
Inmed Pharmaceuticals Inc   8.97 $ 11.810  Millions$ 1.316  Millions
Lipella Pharmaceuticals Inc   8.90 $ 3.429  Millions$ 0.385  Millions
Lipocine Inc   8.74 $ 22.861  Millions$ 2.614  Millions
Neurogene Inc   8.72 $ 200.348  Millions$ 22.973  Millions
Abcellera Biologics Inc   8.72 $ 871.985  Millions$ 100.055  Millions
Xoma Corporation  8.68 $ 169.313  Millions$ 19.499  Millions
Artelo Biosciences Inc   8.51 $ 10.980  Millions$ 1.291  Millions
Capricor Therapeutics inc   8.14 $ 50.855  Millions$ 6.250  Millions
Bicycle Therapeutics Plc  8.08 $ 561.868  Millions$ 69.537  Millions
Alpine Immune Sciences Inc   7.86 $ 330.034  Millions$ 41.980  Millions
Ngm Biopharmaceuticals Inc   7.79 $ 156.444  Millions$ 20.081  Millions
Avidity Biosciences Inc   7.58 $ 611.307  Millions$ 80.680  Millions
Zymeworks Inc   7.41 $ 412.926  Millions$ 55.763  Millions
Xencor Inc  7.36 $ 623.160  Millions$ 84.709  Millions
Salarius Pharmaceuticals inc   7.30 $ 6.520  Millions$ 0.892  Millions
Kronos Bio Inc   7.24 $ 178.778  Millions$ 24.695  Millions
Siga Technologies Inc  7.17 $ 238.991  Millions$ 33.329  Millions
Zentalis Pharmaceuticals Inc   7.16 $ 496.718  Millions$ 69.367  Millions
Werewolf Therapeutics Inc   7.14 $ 138.370  Millions$ 19.378  Millions
Arcutis Biotherapeutics Inc   7.08 $ 330.431  Millions$ 46.668  Millions

Date modified: 2024-03-25T22:15:02+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com